163 related articles for article (PubMed ID: 9306616)
1. Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis.
Minix R; Doctor VM
Thromb Res; 1997 Sep; 87(5):419-29. PubMed ID: 9306616
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the stimulatory effect of native fucoidan, highly sulfated fucoidan and heparin on plasminogen activation by tissue plasminogen activator: the role of chloride.
Lang D; Williams T; Phillips A; Doctor VM
Eur J Drug Metab Pharmacokinet; 2004; 29(4):269-75. PubMed ID: 15726889
[TBL] [Abstract][Full Text] [Related]
3. Effect of fucoidan during activation of human plasminogen.
Doctor VM; Hill C; Jackson GJ
Thromb Res; 1995 Aug; 79(3):237-47. PubMed ID: 8533120
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of enhancement by fucoidan and CNBr-fibrinogen digest of the activation of glu-plasminogen by tissue plasminogen activator.
Muneer E; Bell J; Doctor VM
Eur J Drug Metab Pharmacokinet; 2000; 25(2):137-43. PubMed ID: 11112095
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the synergistic effect between oversulfated chondroitin-6-sulfate and lysine or 6-aminohexanoic acid in enhancing the in-vitro activation of glutamic plasminogen by tissue plasminogen activator or urokinase.
Kouemo S; McMillan E; Doctor V
Blood Coagul Fibrinolysis; 2010 Jul; 21(5):425-30. PubMed ID: 20445443
[TBL] [Abstract][Full Text] [Related]
6. Effect of native fucoidan, sulfated fucoidan, heparin and 6-aminohexanoic acid on the activation of glutamic-plasminogen by urokinase: role of NaCl.
Hall G; Lang D; Qiu X; Doctor V
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):277-81. PubMed ID: 16651870
[TBL] [Abstract][Full Text] [Related]
7. The effect of fucoidan, heparin and cyanogen bromide-fibrinogen on the activation of human glutamic-plasminogen by tissue plasminogen activator.
Bell J; Duhon S; Doctor VM
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):229-34. PubMed ID: 12695744
[TBL] [Abstract][Full Text] [Related]
8. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
Takada A; Shizume K; Cho M; Takada Y
Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
[TBL] [Abstract][Full Text] [Related]
9. The effect of 6-aminohexanoic acid and fucoidan on the activation of glutamic plasminogen by streptokinase.
Harris G; Doctor VM
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):355-9. PubMed ID: 12032402
[TBL] [Abstract][Full Text] [Related]
10. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.
Church FC; Meade JB; Treanor RE; Whinna HC
J Biol Chem; 1989 Feb; 264(6):3618-23. PubMed ID: 2914965
[TBL] [Abstract][Full Text] [Related]
12. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
[TBL] [Abstract][Full Text] [Related]
13. Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin.
Patston PA; Schapira M
Blood; 1994 Aug; 84(4):1164-72. PubMed ID: 8049432
[TBL] [Abstract][Full Text] [Related]
14. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity.
Urano T; Ihara H; Suzuki Y; Takada Y; Takada A
Semin Thromb Hemost; 2000; 26(1):39-42. PubMed ID: 10805280
[TBL] [Abstract][Full Text] [Related]
15. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
17. Effects of a fucoidan on the activation of plasminogen by u-PA and t-PA.
Nishino T; Yamauchi T; Horie M; Nagumo T; Suzuki H
Thromb Res; 2000 Sep; 99(6):623-34. PubMed ID: 10974349
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant low molecular weight heparin does not enhance the activation of plasminogen by tissue plasminogen activator.
Andrade-Gordon P; Strickland S
J Biol Chem; 1989 Sep; 264(26):15177-81. PubMed ID: 2504719
[TBL] [Abstract][Full Text] [Related]
19. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators.
Sitter T; Toet K; Fricke H; Schiffl H; Held E; Kooistra T
Am J Physiol; 1996 Nov; 271(5 Pt 2):R1256-63. PubMed ID: 8945961
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin.
Silverstein RL; Harpel PC; Nachman RL
J Biol Chem; 1986 Jul; 261(21):9959-65. PubMed ID: 2942536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
